PHARMA-SKAN ApS — Credit Rating and Financial Key Figures
CVR number: 16275247
Adelgade 27, 8660 Skanderborg
info@pharma-skan.dk
tel: 87939091
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 12 585.02 | 12 419.94 | 14 799.79 | 15 308.05 | 15 271.78 |
| Costs of management | - 354.13 | - 401.32 | - 402.24 | - 278.36 | - 572.14 |
| Costs of distribution | - 279.12 | - 295.91 | - 434.00 | - 464.46 | - 498.33 |
| EBIT | 11 951.77 | 11 722.70 | 13 963.55 | 14 565.24 | 14 201.30 |
| Other financial income | 0.78 | 48.54 | 178.76 | 274.74 | |
| Other financial expenses | -92.74 | -96.15 | -66.75 | -2.09 | -2.22 |
| Pre-tax profit | 11 859.03 | 11 627.33 | 13 945.34 | 14 741.91 | 14 473.82 |
| Income taxes | -2 608.89 | -2 558.33 | -3 068.11 | -3 243.60 | -3 185.51 |
| Net earnings | 9 250.15 | 9 069.00 | 10 877.23 | 11 498.31 | 11 288.30 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Buildings | 197.38 | 240.72 | 182.49 | 173.29 | 736.85 |
| Advance payments and construction in progress | 101.08 | ||||
| Tangible assets total | 197.38 | 240.72 | 182.49 | 274.37 | 736.85 |
| Investments total | |||||
| Long term receivables total | |||||
| Raw materials and consumables | 2 034.23 | 2 397.45 | 2 400.20 | 3 241.48 | 3 212.07 |
| Inventories total | 2 034.23 | 2 397.45 | 2 400.20 | 3 241.48 | 3 212.07 |
| Current trade debtors | 3 049.44 | 2 814.48 | 4 361.72 | 5 366.84 | 8 331.23 |
| Current amounts owed by group member comp. | 363.64 | 19.70 | 1 022.59 | ||
| Prepayments and accrued income | 110.38 | 75.57 | 53.47 | 24.08 | |
| Current other receivables | 1 399.62 | 4 175.22 | 1 403.04 | 2 373.53 | 2 848.74 |
| Short term receivables total | 4 812.71 | 7 119.79 | 5 840.34 | 7 793.84 | 12 226.64 |
| Cash and bank deposits | 16 547.29 | 11 353.81 | 15 078.30 | 12 251.71 | 7 134.41 |
| Cash and cash equivalents | 16 547.29 | 11 353.81 | 15 078.30 | 12 251.71 | 7 134.41 |
| Balance sheet total (assets) | 23 591.60 | 21 111.76 | 23 501.33 | 23 561.40 | 23 309.97 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 |
| Shares repurchased | 10 000.00 | 9 000.00 | 10 500.00 | 12 000.00 | 9 500.00 |
| Retained earnings | -1 515.18 | -1 265.03 | -2 696.03 | -3 818.80 | -1 820.49 |
| Profit of the financial year | 9 250.15 | 9 069.00 | 10 877.23 | 11 498.31 | 11 288.30 |
| Shareholders equity total | 17 934.97 | 17 003.97 | 18 881.20 | 19 879.51 | 19 167.82 |
| Provisions | 125.90 | 182.30 | 140.60 | 175.30 | 243.40 |
| Non-current liabilities total | |||||
| Current trade creditors | 2 235.08 | 2 389.33 | 853.42 | 861.90 | 819.05 |
| Current owed to group member | 187.50 | 50.81 | 50.81 | ||
| Short-term deferred tax liabilities | 623.81 | 533.90 | |||
| Other non-interest bearing current liabilities | 3 295.66 | 1 348.66 | 2 951.48 | 2 059.98 | 3 079.70 |
| Current liabilities total | 5 530.74 | 3 925.49 | 4 479.52 | 3 506.59 | 3 898.75 |
| Balance sheet total (liabilities) | 23 591.60 | 21 111.76 | 23 501.33 | 23 561.40 | 23 309.97 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.